RNA Q4 2024 Earnings — Avidity Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RNAAvidity Biosciences, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+35.6% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$121M-4069.6% margin

Net Income

-$102M-3439.5% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

+27.3%

Cash Flow

Operating Cash Flow

-$100M

Free Cash Flow

-$104M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$139M

Stockholders' Equity

$1.4B

Cash & Equivalents

$220M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+35.6%
Gross Profit	$3M	$2M	+88.4%
Operating Income	-$121M	-$67M	-81.3%
Net Income	-$102M	-$60M	-69.2%